Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific administrative transaction within a retirement plan rather than general corporate financial performance.
Material Changes
The filing details a revaluation of the cash element of the notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of GSK American Depositary Shares (ADSs) on December 31, 2012, at a price of $43.47 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- The filing reports an increase in notional ADS allocations for specific directors and connected persons due to a plan revaluation.
- The transaction price for the ADSs was $43.47.
- Individuals affected include Dr. M M Slaoui (12 ADSs), Dr. K Slaoui (22 ADSs), Mr. W C Louv (21 ADSs), and Mrs. D P Connelly (1 ADS).
- No financial performance data is included in this specific report.